Several functional signaling pathways submodules that control the cancer cell proliferation participate simultaneously in the cell growth, cell survival, cell differentiation, intracellular senescence and death programs, and in appropriate interaction with angiogenesis, cell microenvironment regulation and immunologic system signaling pathways. Selective targeted drugs of hub molecules may optimize patient's treatment efficacy, such as de use of CDK4/6 inhibitors that improve the outcomes of patients with HR+ breast cancer (BC) [1].